학술논문
Fast and sustained improvement of patient‐reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting.
Document Type
Article
Author
Chicharro, Pablo; Llamas‐Velasco, Mar; Armesto, Susana; Herrera‐Acosta, Enrique; Vidal, David; Vilarrasa, Eva; Rivera, Raquel; De la Cueva, Pablo; Martorell‐Calatayud, Antonio; Ballescà, Ferrán; Belinchón, Isabel; Carretero, Gregorio; Rodríguez, Lourdes; Romero‐Maté, Alberto; Pujol‐Montcusí, Josep; Salgado, Laura; Sahuquillo‐Torralba, Antonio; Coto‐Segura, Pablo; Baniandrés‐Rodríguez, Ofelia; Feltes, Rosa
Source
Subject
*PATIENT reported outcome measures
*TREATMENT effectiveness
*VISUAL analog scale
*BIOTHERAPY
*
*
*
Language
ISSN
1396-0296
Abstract
Psoriasis is a chronic dermatological disease with great impact on patients' quality of life (QoL). The main objective of this study was to assess the impact of secukinumab treatment on different patient‐reported outcomes (PROs) during a long‐term follow‐up in Spanish patients with moderate‐to‐severe psoriasis under real‐world conditions. Retrospective, observational, open‐label, nationwide multicenter cohort study that included patients who initiated treatment with secukinumab in daily clinical practice conditions. PROs assessing disease impact and QoL included Dermatology Life Quality Index (DLQI), Patient's Global Psoriasis Assessment, Itch Numerical Rating Scale and EuroQoL Thermometer Visual Analogue Scale. Outcomes, including PROs and Psoriasis Area and Severity Index (PASI), were assessed at months 3, 6, 12, 18, and 24 during treatment. A total of 238 patients were enrolled in the study. Patients had a mean DLQI score of 14.9 at baseline; 78.3%, 73.7%, and 71.7% of them achieved a DLQI 0/1 response at months 6, 12, and 24, respectively. DLQI score was lower in the long term for naïve patients. A sharp decrease in mean DLQI was observed during the first 3 months, reaching a plateau that was maintained until the end of follow‐up. Similar findings were observed for the rest of QoL assessments. There was a close association between improvement in QoL and skin clearance (PASI), which progressively increased during follow‐up. In this study, secukinumab sustainably improved patient's QoL during a 24‐month follow‐up, with strongest effects in patients naïve to biological therapies and with a direct correlation with PASI improvement. [ABSTRACT FROM AUTHOR]